MARKET

TTNP

TTNP

Titan Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2800
-0.0071
-2.47%
Closed 19:18 07/14 EDT
OPEN
0.2800
PREV CLOSE
0.2871
HIGH
0.2850
LOW
0.2700
VOLUME
4.03M
TURNOVER
--
52 WEEK HIGH
1.250
52 WEEK LOW
0.1420
MARKET CAP
26.78M
P/E (TTM)
-0.3940
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TTNP stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.

EPS

TTNP News

More
Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation
PR Newswire · 6d ago
Titan Pharmaceuticals Says Co's Current Cash Resources Are Only Sufficient To Fund Operations Through Q3 Of This Year
-Reuters
Reuters · 06/30 10:46
Titan Pharmaceuticals Option Alert: Nov 20 $2.5 Calls Sweep (3) near the Ask: 2222 @ $0.051 vs 7425 OI; Earnings 8/12 After Close [est] Ref=$0.42
Benzinga · 06/24 15:03
Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership
PR Newswire · 06/24 13:00
Titan Pharma teams up with Indegene for co-promotion of Probuphine
Seeking Alpha - Article · 06/24 12:36
Titan Pharmaceuticals And Indegene Enter Into Probuphine Co-Promotion Partnership
SAN FRANCISCO, June 24, 2020 /PRNewswire/ --Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with
Benzinga · 06/24 12:08
Titan Pharmaceuticals Launches Virtual REMS Training For Probuphine Health Care Providers
PR Newswire · 06/16 13:00
Titan Pharmaceuticals Launches Virtual REMS Training For Probuphine Health Care Providers
SOUTH SAN FRANCISCO, Calif., June 16, 2020 /PRNewswire/ --Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has initiated a fully-virtual
Benzinga · 06/16 12:02

Industry

Pharmaceuticals
+1.34%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About TTNP

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
More

Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.